US2013244900A1PendingUtilityA1
Gene Expression Profiling in Primary Ovarian Serous Papiliary Tumors and Normal Ovarian Epithelum
Individually held — no corporate assignee on recordPriority: Jun 9, 2003Filed: May 20, 2013Published: Sep 19, 2013
Est. expiryJun 9, 2023(expired)· nominal 20-yr term from priority
Inventors:Alessandro Santin
Y10S977/792C12Q 2600/106A61P 35/00G01N 33/689C12Q 1/6886
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are methods for detecting ovarian serous papillary carcinoma in an individual. A tumor sample from the individual is examined for gene product expression levels of a group of genes consisting of transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family member I (ARHI), thrombospondin 2, and disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2) Gene products which are down-regulated compared to those in a control individual indicate the presence of ovarian serous papillary carcinoma
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of detecting ovarian serous papillary carcinoma in an individual, comprising the steps of:
examining a tumor sample from said individual by the expression levels of gene products of a group of genes consisting of transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family member I (ARHI), thrombospondin 2, and disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2) gene; wherein downregulation of the gene products of said group of genes compared to a control individual indicates that the tumor sample is an ovarian serous papillary carcinoma.
2 . The method of claim 1 , wherein the gene product expression is examined by flow cytometry or immunohistochemical staining.Join the waitlist — get patent alerts
Track US2013244900A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.